Dhukkubni kaansarii proostaatii hammam nama ajjeesa?
Kaansariin proostaataa kaansarii dhiirota addunyaa irratti baay'inaan mul'atu isa lammaffaa yoo ta'u, bara 2018tti dhukkubni haaraan miiliyoona 1.276 kan gabaafame yoo ta'u, dhukkubni kaansarii dhiirota keessatti mul'atu keessaa 7.1% ta'a.
Lakkoofsi du'a kaansarii prostatees ol ka'aa kan ta'e yoo ta'u, bara 2018tti addunyaa irratti namoonni 37,005 du'aniiru jedhamee tilmaama.
Haa ta'u malee, lakkoofsi du'aa naannoorraa gara naannootti baay'ee garaagarummaa kan qabu yoo ta'u, Afrikaa Lixaa addunyaa keessatti balaa du'a kaansarii prostateef sadarkaa shanaffaa kan qabdu yoo ta'u, Naayijeeriyaan ammoo baay'ina uummataa fi dinagdee naannoorraa guddaa qabdi.
Naayijeeriyaa keessatti, kaansariin proostaataa kaansarii dhiirotaaf baay'ee baramaa fi du'aa guddaa kan qabu yoo ta'u, dhiirota kuma 100f 32.8 ta'uu fi 16.3 du'uu danda'a.
Kun lakkoofsa namoota du'anii Ameerikaa Kaabaa keessatti irra harka lama ol ta'a.
Dhukkubni kun yeroodhaa gara yerootti kan mul'atu ta'uunsaa, qoratamuu fi adda ba'uuf meeshaaleen daangeffaman, akkasumas waraqaa fi gabaasni dhukkubichaa hir'achuunsaanii sadarkaa du'aatiin Naayijeeriyaa keessatti ol ka'uu danda'a.
Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H: Trends and characteristics in prostate cancer mortality in Japan. Int J Urol. 2000, 7 (7): 254-7.
Pishgar F, Ebrahimi H, Saeedi Moghaddam S, Fitzmaurice C, Amini E: Global, Regional and National Burden of Prostate Cancer, 1990 to 2015: Results from the Global Burden of Disease Study 2015. J Urol. 2018, 199 (5): 1224-1232.
Cai Q, Chen Y, Zhang D, Pan J, Xie Z, Xu C, Li S, Zhang X, Gao Y, Hou J, Guo X, Zhou X, Zhang B, Ma F, Zhang W, Lin G, Xin Z, Niu Y, Wang Y: Estimates of over-time trends in incidence and mortality of prostate cancer from 1990 to 2030. Transl Androl Urol. 2020, 9 (2): 196-209.
Feletto E, Bang A, Cole-Clark D, Chalasani V, Rasiah K, Smith DP: An examination of prostate cancer trends in Australia, England, Canada and USA: Is the Australian death rate too high? World J Urol. 2015, 33 (11): 1677-87.
Taksler GB, Keating NL, Cutler DM: Explaining racial differences in prostate cancer mortality. Cancer. 2012, 118 (17): 4280-9.
Ejjennoo: fayyaa
Weebsaayitiin kun kaayyoo barnootaa fi odeeffannoo qofaaf kan qophaa'e yoo ta'u, gorsa fayyaa ykn tajaajila ogummaa kennuu miti.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numerical content. For example, the number of people diagnosed with a specific disease.
Yeroo hunda waa'ee dhukkuba tokkoo gorsa ogeessa fayyaa ykn ogeessa fayyaa ga'eessa ta'e biraa gaafadhu. Gorsa fayyaa ogeessaa hin tuffatin ykn waan weebsaayitii kana irratti dubbisteef isa barbaaduu hin daangeffatin. Yoo rakkoo fayyaa qabaachuu dandeessan yoo ta'e, hatattamaan 911 bilbilaa ykn gara kutaa ariifachiisaa dhihoo deemaa. Weebsaayitii kana ykn itti fayyadama isaatiin hariiroon ogeessa fayyaa fi dhukkubsataa hin uumamu. BioMedLib ykn hojjettoonni isaa, ykn namni weebsaayitii kana irratti gumaache kamiyyuu, odeeffannoo asitti kenname ykn itti fayyadama isaa ilaalchisee ibsa ykn yaada hin kennine hin kennine.
Ejjennoo: Mirga bu'uuraa
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the DMCA) abbootii seeraa meeshaaleen intarneetii irratti mul'atan mirga isaanii seera abbaa seerummaa Yunaayitid Isteetis jalatti cabsu jedhanii amanuuf furmaata ni kenna.
DMCA'n beeksiinsi keessan waa'ee cabsaa seeraa kan himatamu odeeffannoo armaan gadii akka dabalatu gaafata: (1) ibsa hojii seeraa kan cabsaa seeraa kan himatamu ta'e; (2) ibsa qabiyyee cabsaa seeraa kan himatamu fi odeeffannoo qabiyyee isaa akka argannu nu dandeessisu ga'aa ta'e; (3) odeeffannoo wal qunnamtii keessan, kan akka teessoo keessan, lakkoofsa bilbilaa fi teessoo iimeelii keessan; (4) ibsi keessan qabiyyee akkaataa komatamanitti akka hin hayyamamne amantaa gaarii akka qabdan ibsa;
(5) beeksifannaa keessatti odeeffannoon sirrii akka ta'e fi mirgi abbaa qabeenyaa akka cabse kan himatamu akka ta'e labsii ati mallatteessite;
fi (6) mallattoo qaamaa ykn elektirooniksii abbaa seeraa ykn nama bakka bu'aa abbaa seeraa ta'uun akka hojjetu hayyamame.
Odeeffannoowwan armaan olitti tarreeffaman hunda kan hin dabalne yoo ta'e, dhimmi komii keessan akka hin mari'atamne gochuu danda'a.
Walitti dhufeenyi
Gaaffii / yaada kamirrayyuu qabdan nutti ergi.
How deadly is prostate cancer?
Prostate cancer is the second most common cancer in men worldwide, with an estimated 1.276 million new cases reported in 2018, representing 7.1% of all cancer cases in men.
The mortality rate for prostate cancer is also high, with an estimated 37,005 deaths worldwide in 2018.
However, the mortality rate varies greatly by region, with Western Africa having the fifth-highest risk for prostate cancer mortality in the world, and Nigeria having the largest population and economy in this region.
In Nigeria, prostate cancer is both the most common and most deadly cancer for men, with an estimated 32.8 cases and 16.3 deaths per 100,000 men.
This is more than double the death rate in North America.
Late detection of the disease, limited resources for screening and detection, and decreased documentation and reporting of cases contribute to the high mortality rate in Nigeria.
In the United States, prostate cancer is the second most common cause of cancer death in men, with approximately 40,0000 men dying from the disease each year.
The prostate cancer death rate has been slowly decreasing since the early 1990s, but it remains a significant health concern.
Overall, prostate cancer is a deadly disease, particularly in regions with limited access to medical care and screening resources.
However, early detection and treatment can significantly improve outcomes and reduce mortality rates.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
Waa'ee
BioMedLib gaaffii fi deebii lama uumuuf kompiitaroota tooftaa (machine-learning algorithms) fayyadama.
